# WuXi Biologics Ireland Wins Top Honors at the 2026 Life Sciences Industry Awards

- Link: https://www.thailand-business-news.com/pr-news/wuxi-biologics-ireland-wins-top-honors-at-the-2026-life-sciences-industry-awards
- Published: 2026-06-08T15:09:00+07:00
- Author: PR Newswire

DUNDALK, Ireland, June 8, 2026 /PRNewswire/ — WuXi Biologics (2269.HK), a leading
global Contract Research, Development and Manufacturing Organization (CRDMO), today
announced that its Ireland site won the "Overall Excellence in Life Sciences" award,
the highest recognition at the 2026 Life Sciences Industry Awards. The company also
was named the winner of the "Life Sciences Team of the Year" and won the "Outstanding
Contribution Award." The Life Sciences Industry Awards are among Ireland’s foremost
industry recognition programs, celebrating excellence, innovation, and leadership
across the country’s pharmaceutical, biotechnology, medical device, and broader 
life sciences sectors.

The company was shortlisted across eight award categories, reflecting the breadth
of capabilities and achievements demonstrated by its Ireland site. Among the honors
received, WuXi Biologics’ Manufacturing Science & Technology (MSAT) Team was named
Life Sciences Team of the Year and subsequently selected for the Overall Excellence
in Life Sciences award, recognizing the team’s exceptional contributions to advancing
manufacturing science, technology transfer, operational performance, and delivery
excellence.

The recognition further reinforces WuXi Biologics Ireland’s position as a strategic
hub within the company’s global network and highlights its continued commitment 
to quality, innovation, operational excellence, and sustainable growth. As demand
for high-quality biologics manufacturing continues to grow, the Ireland site remains
focused on delivering flexible and reliable solutions that support global clients
across the development and commercialization lifecycle.

These latest honors build upon a series of major milestones achieved by the Ireland
site in recent years, including HPRA GMP authorization and EMA approval for commercial
manufacturing of innovative biologic products. Since commencing operations, the 
WuXi Biologics Ireland site has established itself as one of Europe’s most advanced
single-use biologics manufacturing facilities, earning international recognition
for its operational excellence, innovation, and sustainability performance.  

Other accolades the Ireland site has received include the ISPE Facility of the Year
Award and the Operational Excellence in Life Sciences Award. All together, these
achievements underscore the site’s growing role in supporting global biologics development
and commercial manufacturing while contributing to the continued advancement of 
Ireland’s thriving life sciences ecosystem.

WuXi Biologics’ global manufacturing footprint spans China, the United States, Ireland,
Germany, and Singapore, with 24 drug substance (DS) facilities and 18 drug product(
DP) facilities currently in operation. This network provides integrated dual-sourcing
solutions spanning DS and DP — from clinical development through commercial-scale
manufacturing — at the highest levels of quality. As of 2025, WuXi Biologics had
successfully passed 46 regulatory inspections worldwide, including 22 conducted 
by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency(
EMA), achieving a 100% success rate with no critical findings and no data integrity
issues.

**About WuXi Biologics**

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development
and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable
partners to discover, develop and manufacture biologics – from concept to commercialization–
for the benefit of patients worldwide*.

With over 13,000 employees in China, the United States, Ireland, Germany, and Singapore—
including experts and scientists in biologics R&D and manufacturing, technology 
innovation, and operational excellence — WuXi Biologics leverages its technologies
and expertise to deliver efficient, cost-effective, and scalable biologics solutions
tailored to meet clients’ needs. By embedding digital capability and infrastructure
across the full biopharmaceutical value chain, the company turns data, computation,
and prediction into transparent client experience, faster development, intelligent
operations, and more efficient manufacturing. As of April 30, 2026, WuXi Biologics
is supporting 982 integrated client projects, including 78 in Phase III and 25 in
commercial manufacturing, with complex modalities representing more than half of
the entire project portfolio.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth.
The company continuously drives technology innovations to offer advanced end-to-
end Green CRDMO solutions for its global partners while demonstrating exemplary 
Environmental, Social and Governance (ESG) practices. Committed to creating shared
value, it collaborates with all stakeholders to foster positive social and environmental
impacts, and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: [www.wuxibiologics.com](http://www.wuxibiologics.com/).

*The winner of the "2026 Biologics CDMO of the Year" (Large CDMOs) (Life Science
Connect / Outsourced Pharma)
*The winner of the "2026 Best Contract Development &
Manufacturing Organization Award" (ABEA)

**ContactsBusiness
[info@wuxibiologics.com](https://www.thailand-business-news.com/pr-news/info@wuxibiologics.com)

Media
[PR@wuxibiologics.com](https://www.thailand-business-news.com/pr-news/PR@wuxibiologics.com)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [WuXi Biologics Ireland Wins Top Honors at the 2026 Life Sciences Industry Awards ](http://www.prnasia.com/story/archive/4978022_CN78022_0?rand=184833)
